Expert Review of Cardiovascular Therapy最新文献_第5页

Current status and future directions in artificial intelligence for nuclear cardiology. 核心脏病学人工智能的现状和未来方向。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-16 DOI: 10.1080/14779072.2024.2380764

Robert J H Miller, Piotr J Slomka

{"title":"Current status and future directions in artificial intelligence for nuclear cardiology.","authors":"Robert J H Miller, Piotr J Slomka","doi":"10.1080/14779072.2024.2380764","DOIUrl":"10.1080/14779072.2024.2380764","url":null,"abstract":"Introduction: Myocardial perfusion imaging (MPI) is one of the most commonly ordered cardiac imaging tests. Accurate motion correction, image registration, and reconstruction are critical for high-quality imaging, but this can be technically challenging and has traditionally relied on expert manual processing. With accurate processing, there is a rich variety of clinical, stress, functional, and anatomic data that can be integrated to guide patient management.Areas covered: PubMed and Google Scholar were reviewed for articles related to artificial intelligence in nuclear cardiology published between 2020 and 2024. We will outline the prominent roles for artificial intelligence (AI) solutions to provide motion correction, image registration, and reconstruction. We will review the role for AI in extracting anatomic data for hybrid MPI which is otherwise neglected. Lastly, we will discuss AI methods to integrate the wealth of data to improve disease diagnosis or risk stratification.Expert opinion: There is growing evidence that AI will transform the performance of MPI by automating and improving on aspects of image acquisition and reconstruction. Physicians and researchers will need to understand the potential strengths of AI in order to benefit from the full clinical utility of MPI.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"367-378"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cerebral embolic protection for stroke prevention during transcatheter aortic valve replacement. 经导管主动脉瓣置换术中预防中风的脑栓塞保护。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI: 10.1080/14779072.2024.2385989

Jawad Basit, Mushood Ahmed, George Kidess, Zaofashan Zaheer, Laveeza Fatima, Hamza Naveed, Mohammad Hamza, Maurish Fatima, Aman Goyal, Pranav Loyalka, Mahboob Alam, M Chadi Alraies

{"title":"Cerebral embolic protection for stroke prevention during transcatheter aortic valve replacement.","authors":"Jawad Basit, Mushood Ahmed, George Kidess, Zaofashan Zaheer, Laveeza Fatima, Hamza Naveed, Mohammad Hamza, Maurish Fatima, Aman Goyal, Pranav Loyalka, Mahboob Alam, M Chadi Alraies","doi":"10.1080/14779072.2024.2385989","DOIUrl":"10.1080/14779072.2024.2385989","url":null,"abstract":"Introduction: Cerebral Embolic Protection Device (CEPD) captures emboli during Transcatheter Aortic Valve Replacement (TAVR). With recently published pivotal trials and multiple cohort studies reporting new data, there is a need to re-calibrate available statistical evidence.Methods: A systematic literature search was conducted across databases from inception till February 2023. Dichotomous outcomes were pooled using Odds Ratio (OR), while continuous outcomes were pooled using Standardized Mean Difference (SMD) along with 95% corresponding intervals (95% CIs).Results: Data was included from 17 studies (7 RCTs, 10 cohorts, n = 155,829). Use of CEPD was associated with significantly reduced odds of stroke (OR = 0.60, 95% CI = 0.43-0.85, p = 0.003). There was no significant difference in disabling stroke (p = 0.25), non-disabling stroke (p = 0.72), and 30-day mortality (p = 0.10) between the two groups. There were no significant differences between the two groups for Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) findings, acute kidney injury, risk of pacemaker implantation life-threatening bleed, major bleed, minor bleed, worsening National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) and vascular complications (p > 0.05).Conclusions: The use of CEPD during TAVR reduced the incidence of all-stroke (p = 0.003); however, there were no significant differences in any of the other pooled outcomes (p > 0.05).Registration: The protocol of this meta-analysis was registered with the Open Science framework [https://doi.org/10.17605/OSF.IO/7W564] before data acquisition was started.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"409-420"},"PeriodicalIF":1.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of statin therapy in older adults: best practices and unmet challenges. 他汀类药物治疗在老年人中的作用：最佳实践和尚未应对的挑战。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-07-01 DOI: 10.1080/14779072.2024.2371968

John Stone, Manish Kumar, Ariela R Orkaby

{"title":"The role of statin therapy in older adults: best practices and unmet challenges.","authors":"John Stone, Manish Kumar, Ariela R Orkaby","doi":"10.1080/14779072.2024.2371968","DOIUrl":"10.1080/14779072.2024.2371968","url":null,"abstract":"Introduction: Cardiovascular disease (CVD) is associated with significant morbidity, functional decline, and mortality in older adults. The role of statins for primary CVD prevention in older adults remains unclear, largely due to systematic exclusion of these individuals in trials that inform current practice guidelines, leading to conflicting national and international practice recommendations for statin use for primary prevention of CVD in adults aged 75 and older.Areas covered: In this narrative review, we performed a literature review utilizing PubMed, and ultimately focus on seven major national and international guidelines of lipid lowering therapy. Through the lens of two clinical cases, we review physiologic changes in lipid metabolism with aging, discuss the relationship between cholesterol and cardiovascular events in older adults, examine the national and international guidelines and the available evidence informing these guidelines for statin use in primary prevention of CVD in older adults. Finally we review practical clinical considerations for drug monitoring and deprescribing in this population.Expert opinion: Guidelines for the use of statins for primary CVD prevention in older adults is conflicting. Collectively, evidence to date suggests statin therapy may be beneficial for primary CVD prevention in older adults free of life-limiting comorbidities. Randomized controlled trials are currently underway to address current evidence gaps.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"301-311"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation. 心房颤动经皮冠状动脉介入治疗后的三联抗血栓治疗持续时间和临床疗效。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-07-01 DOI: 10.1080/14779072.2024.2374366

Mark A Sammut, Dwayne Conway, Javaid Iqbal, Arvindra Krishnamurthy, Kenneth P Morgan, Paul D Morris, James D Richardson, Alexander M K Rothman, Julian P Gunn, Robert F Storey

{"title":"Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation.","authors":"Mark A Sammut, Dwayne Conway, Javaid Iqbal, Arvindra Krishnamurthy, Kenneth P Morgan, Paul D Morris, James D Richardson, Alexander M K Rothman, Julian P Gunn, Robert F Storey","doi":"10.1080/14779072.2024.2374366","DOIUrl":"10.1080/14779072.2024.2374366","url":null,"abstract":"Background: Triple antithrombotic therapy (TAT) with aspirin, a P2Y12 inhibitor, and oral anticoagulation in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raises concerns about increased bleeding. Regimens incorporating more potent P2Y12 inhibitors over clopidogrel have not been investigated adequately.Research design and methods: A retrospective observational study was performed on 387 patients with AF receiving TAT for 1 month (n = 236) or ≤1 week (n = 151) after PCI. Major and clinically relevant non-major bleeding and major adverse cardiac and cerebrovascular events (MACCE) were assessed up to 30 days post-procedure.Results: Bleeding was less frequent with ≤1 week versus 1 month of TAT (3.3 vs 9.3%; p = 0.025) while MACCE were similar (4.6 vs 4.7%; p = 0.998). No differences in bleeding or MACCE were observed between ticagrelor/prasugrel and clopidogrel regimens. For patients receiving ≤1 week of TAT, no excess of MACCE was seen in the subgroup given no further aspirin post-PCI compared with those given aspirin for up to 1 week (3.6 vs 5.2%).Conclusions: TAT post-PCI for ≤1 week was associated with less bleeding despite greater use of ticagrelor/prasugrel but similar MACCE versus 1-month TAT. These findings support further studies on safety and efficacy of dual therapy with ticagrelor/prasugrel immediately after PCI.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"339-345"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ischemic stroke and the emerging role of left atrial function. 缺血性中风和左心房功能的新作用。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-07-01 Epub Date: 2024-06-29 DOI: 10.1080/14779072.2024.2370814

Bjørn Strøier Larsen, Tor Biering-Sørensen, Flemming Javier Olsen

{"title":"Ischemic stroke and the emerging role of left atrial function.","authors":"Bjørn Strøier Larsen, Tor Biering-Sørensen, Flemming Javier Olsen","doi":"10.1080/14779072.2024.2370814","DOIUrl":"10.1080/14779072.2024.2370814","url":null,"abstract":"Introduction: Ischemic stroke is a leading cause of morbidity and mortality worldwide. Emerging evidence suggests that left atrial (LA) dysfunction could play a role in the pathophysiology of ischemic stroke, as a possible contributor and as a predictive biomarker.Areas covered: This narrative review details the intricate relationship between LA function, atrial fibrillation (AF), and ischemic stroke. We discuss imaging techniques used to assess LA function, the mechanisms by which impaired LA function may contribute to stroke, and its potential as a prognostic marker of stroke.Expert opinion: There is a lack of evidence-based treatments of LA dysfunction in both primary and secondary stroke prevention. This is partly due to the lack of a practical clinical definition and unanswered questions concerning the clinical implications of LA dysfunction in patients without AF. Until such questions are resolved, addressing well-known cardiovascular risk factors, like hypertension and obesity, should be prioritized for preventing AF and ischemic stroke. These risk factors are closely tied to atrial remodeling, emphasizing the importance of targeting primary modifiable factors for preventing future morbidity and mortality.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"289-300"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel balloon-expandable transcatheter aortic valve bioprosthesis: Myval and Myval Octacor. 新型球囊扩张经导管主动脉瓣生物假体：myval 和 myval Octacor。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-07-01 Epub Date: 2024-07-15 DOI: 10.1080/14779072.2024.2375345

Carolina Montonati, Dario Pellegrini, Daniele Oreste d'Atri, Mariano Pellicano, Daniele Briguglia, Francesco Giannini, Giuseppe De Blasio, Giulio Guagliumi, Maurizio Tespili, Alfonso Ielasi

{"title":"A novel balloon-expandable transcatheter aortic valve bioprosthesis: Myval and Myval Octacor.","authors":"Carolina Montonati, Dario Pellegrini, Daniele Oreste d'Atri, Mariano Pellicano, Daniele Briguglia, Francesco Giannini, Giuseppe De Blasio, Giulio Guagliumi, Maurizio Tespili, Alfonso Ielasi","doi":"10.1080/14779072.2024.2375345","DOIUrl":"10.1080/14779072.2024.2375345","url":null,"abstract":"Introduction: Over the past two decades, transcatheter aortic valve replacement (TAVR) has expanded its application across all surgical risk levels, including low-risk patients, where, due to longer life expectancy, reducing common pitfalls of TAVR is essential. To address these needs, many technological advancements have been developed. Myval and the new generation Myval Octacor (Meril Life Sciences Pvt. Ltd) are novel balloon-expandable (BE) transcatheter heart valve (THV) systems designed for the treatment of severe aortic stenosis.Areas covered: This review aims to illustrate the design features of these novel THVs and the main evidence from available studies. Furthermore, we provide evidence of these THVs' performance in challenging scenarios such as extra-large aortic annuli, bicuspid aortic valves, and valve-in-valve/valve-in-ring procedures.Expert opinion: Myval and Myval Octacor have demonstrated comparable early safety and clinical efficacy to the leading contemporary THVs, exhibiting remarkably low rates of moderate to severe paravalvular leak (PVL) and permanent pacemaker implantation (PPI). The wide range of sizes offered by the Myval family may minimize the risk of under-/oversizing, potentially explaining the lower rates of the aforementioned phenomena. Moreover, the presence of both internal skirt and external reinforced cuff may also explain the low rate of moderate to severe PVL.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"325-337"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-based approaches for reducing stroke risk: an update on their success and the challenges ahead. 降低中风风险的人群方法：成功经验与未来挑战的最新进展。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-07-01 Epub Date: 2024-06-26 DOI: 10.1080/14779072.2024.2372447

Taylor R Anderson, Kasim Qureshi, Muhammad U Farooq, Philip B Gorelick

{"title":"Population-based approaches for reducing stroke risk: an update on their success and the challenges ahead.","authors":"Taylor R Anderson, Kasim Qureshi, Muhammad U Farooq, Philip B Gorelick","doi":"10.1080/14779072.2024.2372447","DOIUrl":"10.1080/14779072.2024.2372447","url":null,"abstract":"Introduction: Stroke is a significant public health challenge as it is the second most common cause of death and the third leading cause of disability globally. Additionally, stroke incidence and the number of stroke deaths have been rising. Efforts to prevent stroke have been made, including high-risk approaches where patients are screened for cardiovascular risk factors, and population-based approaches which attempt to reduce stroke rates by improving overall population health.Areas covered: We summarize studies of population-based approaches to stroke prevention involving greater than 1,000 participants identified on a PubMed database search. Based on these programs, challenges of population-based stroke prevention programs are discussed and potential keys to success are highlighted.Expert opinion: Population-based stroke prevention programs face challenges including cost and interest of the public and certain stakeholders. Additionally, secular trends for improvement in risk factors and catastrophic adverse environmental circumstances add to the complexity of analyzing program success. Factors leading to successful programs include validated digital solutions for self-monitoring of risks, backing by global policy and legislation, flexibility to the needs of the population, intersectoral programs, community engagement, information dissemination back to the populations, and high-risk screening to develop a complementary combination approach to stroke prevention.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"313-324"},"PeriodicalIF":1.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual chamber leadless pacemaker: a game changer for bradycardia management? 双腔无导线起搏器：心动过缓治疗的变革者？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-07-01 Epub Date: 2024-07-11 DOI: 10.1080/14779072.2024.2375331

Lin-Thiri Toon, John Paisey, Paul R Roberts

引用次数: 0

Sex differences in acute myocardial infarction. 急性心肌梗死的性别差异。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-06-01 Epub Date: 2024-06-02 DOI: 10.1080/14779072.2024.2362182

Elizabeth G Dieter Aravinda Nanjundappa

引用次数: 0

Targeting obesity for therapeutic intervention in heart failure patients. 针对肥胖症对心力衰竭患者进行治疗干预。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-06-01 Epub Date: 2024-06-13 DOI: 10.1080/14779072.2024.2363395

Ryosuke Sato, Stephan von Haehling

{"title":"Targeting obesity for therapeutic intervention in heart failure patients.","authors":"Ryosuke Sato, Stephan von Haehling","doi":"10.1080/14779072.2024.2363395","DOIUrl":"10.1080/14779072.2024.2363395","url":null,"abstract":"Introduction: Heart failure with preserved ejection fraction (HFpEF) is a highly heterogeneous syndrome, making it challenging to improve prognosis with pharmacotherapy. Obesity is one of the leading phenotypes of HFpEF, and its prevalence continues to grow worldwide. Consequently, obesity-targeted interventions have attracted attention as a novel treatment strategy for HFpEF.Areas covered: The authors review the association between the pathogenesis of obesity and HFpEF and the potential for obesity-targeted pharmacotherapeutic strategies in HFpEF, together with the latest evidence. The literature search was conducted in PubMed up to April 2024.Expert opinion: The STEP HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trials recently demonstrated that the glucagon-like peptide 1 analogue, semaglutide, improves various aspects of clinical outcomes in obese HFpEF patients and significantly reduces cardiovascular and heart failure events in non-diabetic obese patients, along with a substantial weight loss. Future clinical trials with other incretin mimetics with more potent weight loss and sub-analyses of the SELECT trial may further emphasize the importance of the obesity phenotype-based approach in the treatment of HFpEF.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"217-230"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0